Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Selank (SEL) is a cognitive peptide, at the approved in russia stage in the published literature. Synthetic analog of the immunomodulatory peptide tuftsin with anxiolytic and nootropic properties. Developed alongside Semax in Russia.
Synthetic analog of the immunomodulatory peptide tuftsin with anxiolytic and nootropic properties. Developed alongside Semax in Russia.
| Research Status | Approved in Russia |
|---|---|
| Half-Life | Minutes (rapid absorption) |
| Administration | Intranasal |
| Doses Reported in Published Studies | 250-500 mcg |
Modulates GABA, serotonin, and dopamine systems. Increases BDNF expression and reduces anxiety.
Synthetic analog of the immunomodulatory peptide tuftsin with anxiolytic and nootropic properties. Developed alongside Semax in Russia.
Modulates GABA, serotonin, and dopamine systems. Increases BDNF expression and reduces anxiety.
Selank is at the following stage in the published literature: Approved in Russia. All information is for research and educational purposes only.
Reported half-life: Minutes (rapid absorption).
Reported administration route in the literature: Intranasal. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.